AIM ImmunoTech Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.164 USD (Oct 30, 2026, 9:30 AM EDT) · Market cap 4.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Details
| Name | AIM ImmunoTech Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 21 |
| Founded | 1966 |
| Ceo | Thomas Equels |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US00901B3033 |
| Cusip | 00901B303 |
| Cik | 946644 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Thomas K. Equels Esq., J.D., M.S. | Executive Vice Chairman, Chief Executive Officer and President |
| Robert Dickey IV, B.A., M.B.A. | Chief Financial Officer |
| Peter W. Rodino III, Esq., J.D. | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel and Secretary |
| Ann Marie E. Coverly | Director of Administration and Human Resources and Deputy Investor Relations Coordinator |
| Dr. Christopher Nicodemus FACP, M.D. | Member of Scientific Advisory Board and Consulting Science Officer |
Contact
| Address | 2117 SW Highway 484, Ocala, Florida 34473, United States |
| Phone | 352 448 7797 |
| Website | https://aimimmuno.com |